Clinical Trial Update: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma [Phase 2]

View source ↗

Summary

An NCI-sponsored Phase 2 trial is evaluating belinostat in combination with guadecitabine (SGI-110) or with ASTX727 for unresectable and metastatic conventional…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conventional Chondrosarcoma

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Belinostat (Beleodaq) (belinostat)
• Guadecitabine (SGI-110) (guadecitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-09-16